- Home
- RYTM vs ESE Comparison
RYTM vs ESE Comparison
Compare RYTM & ESE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- ESE
- Stock Information
- Founded
- RYTM 2008
- ESE 1990
- Country
- RYTM United States
- ESE United States
- Employees
- RYTM N/A
- ESE N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- ESE Telecommunications Equipment
- Sector
- RYTM Health Care
- ESE Telecommunications
- Exchange
- RYTM Nasdaq
- ESE Nasdaq
- Market Cap
- RYTM 3.5B
- ESE 3.4B
- IPO Year
- RYTM 2017
- ESE N/A
- Fundamental
- Price
- RYTM $56.07
- ESE $162.12
- Analyst Decision
- RYTM Strong Buy
- ESE Strong Buy
- Analyst Count
- RYTM 10
- ESE 2
- Target Price
- RYTM $66.90
- ESE $147.50
- AVG Volume (30 Days)
- RYTM 380.5K
- ESE 125.6K
- Earning Date
- RYTM 02-26-2025
- ESE 02-06-2025
- Dividend Yield
- RYTM N/A
- ESE 0.19%
- EPS Growth
- RYTM N/A
- ESE 18.29
- EPS
- RYTM N/A
- ESE 4.26
- Revenue
- RYTM $112,530,000.00
- ESE $1,055,471,000.00
- Revenue This Year
- RYTM $66.58
- ESE $14.05
- Revenue Next Year
- RYTM $44.63
- ESE $11.19
- P/E Ratio
- RYTM N/A
- ESE $40.07
- Revenue Growth
- RYTM 81.55
- ESE 8.94
- 52 Week Low
- RYTM $35.17
- ESE $97.11
- 52 Week High
- RYTM $68.58
- ESE $171.28
- Technical
- Relative Strength Index (RSI)
- RYTM 42.18
- ESE 65.15
- Support Level
- RYTM $56.03
- ESE $160.23
- Resistance Level
- RYTM $58.65
- ESE $167.61
- Average True Range (ATR)
- RYTM 1.87
- ESE 6.00
- MACD
- RYTM -0.27
- ESE 1.88
- Stochastic Oscillator
- RYTM 5.45
- ESE 79.56
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About ESE ESCO Technologies Inc.
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace and Defense, Utility Solutions Group (USG) and RF Shielding and Test (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure and contain magnetic, electromagnetic and acoustic energy.